Expanding the Reach of Antibody–Drug Conjugates
- 15 September 2016
- journal article
- editorial
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 7 (11) , 974-976
Abstract
Antibody–drug conjugates (ADCs) represent an emerging new paradigm in cancer therapy. The approval of two ADCs has spurred considerable interest in this area of research, and over 55 ADCs are currently in clinical testing. In order to improve the clinical success rate of ADC therapy, all three components of the ADC: the antibody, linker, and payload have to be optimized. While considerable improvements have been made in antibody properties and target selection, medicinal chemistry efforts have lagged behind, and there is a significant need for innovation in linker design and payloads.Keywords
This publication has 11 references indexed in Scilit:
- Natural Product Splicing Inhibitors: A New Class of Antibody–Drug Conjugate (ADC) PayloadsBioconjugate Chemistry, 2016
- A New Triglycyl Peptide Linker for Antibody–Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer CellsMolecular Cancer Therapeutics, 2016
- A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted TherapyCancer Cell, 2016
- Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug DevelopmentBioconjugate Chemistry, 2014
- Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal ModificationsJournal of Medicinal Chemistry, 2014
- Antibody–Drug Conjugates: An Emerging Concept in Cancer TherapyAngewandte Chemie International Edition, 2014
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive LymphomasNew England Journal of Medicine, 2010
- Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast CancerJournal of Clinical Oncology, 2010
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic indexNature Biotechnology, 2008
- Targeted Cancer Therapy: Conferring Specificity to Cytotoxic DrugsAccounts of Chemical Research, 2007